Oncogene forms marketing alliance in Japan:
This article was originally published in Clinica
Oncogene Science Diagnostics has formed a four-year alliance with Tokyo-based company Fujirebio to develop, manufacture and sell cancer diagnostic products in Japan. Fujirebio has received a non-exclusive licence to develop a range of cancer assays based on Oncogene's proprietary technology. The assays will be formatted on Fujirebio's automated clinical system, Lumipulse. The Uniondale, New York-based company will receive royalties on product sales, licensing fees and R&D funding. Oncogene expects the launch of the first newly-developed assay later next year.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.